The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

MediaNamaAsia

PharmEasy parent trims FY26 loss to Rs 520 crore on shift to high-margin businesses

October 13

API Holdings, the parent of healthtech startup PharmEasy, narrowed its consolidated net loss by 67% to Rs 520 crore in the year ended March 2026 from Rs 1,572 crore in the previous fiscal year…

Read at MediaNama ↗

One letter a week, starting soon.

Latest

PharmEasy parent trims FY26 loss to Rs 520 crore on shift to high-margin businesses

More from MediaNama on Accept All

AsiaMeta tells Bombay HC it disabled Blink Digital’s ad accounts over alleged scam and sexual services ads MediaNama

AsiaTurkey bans social media for under-15s, restricts infinite scrolling, ads and algorithms for teenagers MediaNama

AsiaDelhi HC: BJP MP and actor Kangana Ranaut gets personality rights protections against deepfakes, false quotes MediaNama